

Special Issue

Gynecological Cancer: Molecular Oncology and the Use of Emerging Technologies in Relation to Early Detection and Treatment

Message from the Guest Editor

It is clear that the incidence of gynaecological cancers is on the increase and due to the different forms of gynaecological cancer, different therapeutic approaches are required. This open-access Special Issue will bring together original research and review articles on molecular oncology and the use of emerging technologies in relation to the early detection and treatment of cancers. It highlights new findings, methods, and technical advances in gynaecological cancer research. The main feature of this Special Issue is to provide open-source sharing of significant works in the field of gynaecological cancer that will increase our understanding of cancer development, and may lead to the discovery of new molecular diagnostic technologies and better targeted therapeutics. Topics include but are not limited to: Molecular methods for better gynaecological cancer screening and detection. New technology for better targeted therapies to prevent cancer development and metastases. Identification and new aspects of cellular signalling molecules and pathways for target discovery, patient prognosis, future drug design, and better patient outcomes.

Guest Editor

Dr. Anthony Taylor
Leicester Medical School, University of Leicester, Leicester, UK

Deadline for manuscript submissions

closed (29 January 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/136546

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)